

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	12/NE/0323	112876	An Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination with Either Gemcitabine or Cisplatin and Etoposide in Subjects with Advanced Solid Tumors	Number Agreed	17	17	Date Agreed	01/09/2017	26	19/05/2017	26	Recruitment finished	
2	14/NW/0352	148901	Phase 3b/4 randomised safety endpoint study of 2 doses of Tofacitinib in comparison to a TNF inhibitor in subjects with Rheumatoid Arthritis	Range Agreed	2	4	Date Agreed	19/08/2017	2	29/06/2017	2	Recruitment finished	
3	13/EE/0126	129195	Evaluation of Safety and Efficacy of the BACE™ [Basal Annuloplasty of the Cardia Externally] Device in the Treatment of Functional Mitral Valve Regurgitation [FMR]	Number Agreed	1	1	Date Agreed	31/12/2017	0	30/06/2017	0	Withdrawn by sponsor	Sponsor closed study in the UK after three years of not being able to recruit any patients
4	15/NE/0159	177377	Clinical Study of the BreathID® System to train the algorithm for the 13C-Octanoate Breath Test with or without the 13C-Methacetin Breath Test (OBT and MBT respectively) for correlation with histological findings of Non-Alcoholic Fatty Liver Disease (NAFLD).	Range Agreed	10	20	Date Agreed	30/06/2017	9	01/06/2017	9	Withdrawn by sponsor	Sponsor reached a significant number of subjects and decided to terminate the study
5	15/EE/0352	183058	A Phase 3, Randomised, Parallel-Group, Active-Controlled, Double-Blind Study to Compare Efficacy and Safety between CT-P10 and Rituxan in Patients with Low Tumour Burden Follicular Lymphoma	Number Agreed	7	7	Date Agreed	28/02/2018	7	06/06/2017	7	Recruitment finished	
6	15/LO/1598	178793	A Phase III, Multicenter, Randomized, Double Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Tocilizumab versus Placebo in Patients with Systemic Sclerosis	Range Agreed	1	2	Date Agreed	31/05/2017	1	31/05/2017	1	Recruitment finished	
7	15/SW/0274	185069	A Randomized, Double-blind, Comparative Study of JNJ-56021927 plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Subjects with Metastatic Hormone-Sensitive Prostate Cancer (Mhspc) - TITAN	Number Agreed	5	5	Date Agreed	05/04/2018	6	31/05/2017	6	Recruitment finished	
8	14/SS/1087	164169	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of a Titrated Immediate-release selective arginine vasopressin type 2 receptor antagonist (30 mg to 120 mg/day, Split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease (protocol 156-13-211)	Number Agreed	3	3	Date Agreed	31/12/2017	3	18/05/2017	3	Recruitment finished	
9	16/NE/0189	207061	A Phase 3b Open-label Extension Study to Evaluate the Safety and Efficacy of Aceneuramic Acid Extended-Release (Acer) Tablets in Patients with GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)	Number Agreed	18	18	Date Agreed	30/06/2017	18	18/06/2017	18	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
10	15/EE/0448	189797	Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma	Range Agreed	1	5	Date Agreed	30/06/2017	2	30/06/2017	2	Recruitment finished	
11	16/EE/0133	202599	Safety and proof of principle study of ATX-GD-59 in male and female subjects with Graves' disease not currently treated with anti-thyroid therapy: An Open label study, with an upward titration over five dose levels administered by intradermal injection.	Range Agreed	3	10	Date Agreed	15/06/2017	3	15/06/2017	3	Recruitment finished	
12	16/LO/1001	199167	Randomized, double-blind, placebo-controlled exploratory study to evaluate pharmacodynamics, safety and tolerability of orally administered BI 1026706 for 12 weeks in patients with visual impairment due to central involved diabetic macular edema (DME)	Range Agreed	1	4	Date Agreed	12/05/2017	1	12/05/2017	1	Recruitment finished	
13	16/LO/0138	192464	A phase III study of Lenalidomide and low-dose Dexamethasone with or without Pembrolizumab (MK3475) in newly diagnosed and treatment naïve Multiple Myeloma (KEYNOTE 185)	Range Agreed	3	6	Date Agreed	23/05/2017	2	12/05/2017	2	Withdrawn by sponsor	Recruitment was stopped nationally due to safety reasons
14	16/WM/0247	202461	A MULTI-CENTER, RETROSPECTIVE OBSERVATIONAL STUDY OF REAL-WORLD EXPERIENCE OF PSORIASIS PATIENTS TREATED WITH APREMILAST IN CLINICAL DERMATOLOGY PRACTICE	Number Agreed	6	6	Date Agreed	17/08/2016	6	24/06/2017	6	Recruitment finished	
15	16/LO/1511	210799	Evaluation of the Clinical Performance of the Alere HBsAg Rapid Test	Range Agreed	30	80	Date Agreed	19/05/2017	84	19/05/2017	84	Recruitment finished	
16	16/SC/0515	215537	A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation, and Bioavailability Study Evaluating the Safety and Pharmacokinetics of VX-659 in Healthy Subjects and in Subjects With Cystic Fibrosis	Number Agreed	1	1	Date Agreed	31/05/2017	1	31/05/2017	1	Recruitment finished	
17	16/EE/0506	213985	Short term outcomes of Donation after Circulatory Death (DCD) renal transplantation in the United Kingdom	Number Agreed	30	30	Date Agreed	31/05/2017	84	31/05/2017	84	Recruitment finished	
18	15/YH/0535	190077	A multicentre, randomised, open-label, parallel-group study to demonstrate the safety and tolerability of early pre-discharge initiation of LCZ696 compared to standard of care for ACEI/ARB followed by post-discharge initiation of LCZ696 in HRrEF patients	Number Agreed	5	5	Date Agreed	29/08/2017	5	18/05/2017	5	Recruitment finished	
19	16/EE/0195	200168	A randomized, double-blind phase III study of vadastuximab taririne (SGN-CD33A) versus placebo in combination with azacitidine or decitabine in the treatment of older patients with newly diagnosed acute myeloid leukaemia (AML) - CASCADE	Range Agreed	2	6	Date Agreed	30/06/2018	3	19/06/2017	3	Withdrawn by sponsor	Sponsor decided to discontinue the study due to safety measures with the drug

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
20	14/SC/1192	159400	An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 following a Single Oral Dose to Patients with Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment	Number Agreed	2	2	Date Agreed	30/04/2017	1	30/04/2017	1	Recruitment finished	Original target was set when the sponsor agreed to the slot allocation. This allocation was changed by the sponsor post start up. The remaining cohort of patients were very rare and we were unable to find a suitable participant
21	13/LO/1265	135103	FIRST-IN-HUMAN, DOSE-ESCALATING SAFETY STUDY OF TISSUE FACTOR SPECIFIC ANTIBODY DRUG CONJUGATE (HUMAX®-TF-ADC) IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS KNOWN TO EXPRESS TISSUE FACTOR	Range Agreed	9	13	Date Agreed	30/04/2017	10	30/04/2017	10	Recruitment finished	
22	13/YH/0086	125247	"STUDY LT4020-PIII-12/1: 1Efficacy and Safety Assessment of T4020 Versus Vehicle in Patients with Chronic Neutrophilic Keratitis or Corneal Ulcer. Phase III study, international, multicentre, randomized, double-masked, 2 parallel groups, versus vehicle, in 124 evaluable patients treated for 28 days."	Range Agreed	2	3	Date Agreed	01/04/2017	2	01/04/2017	2	Recruitment finished	
23	14/LO/2182	143226	A Phase III Clinical Trial of Intra-arterial TheraSphere® in the Treatment of Patients with Unresectable Hepatocellular Carcinoma (HCC) (protocol ID: TS103) STOP study	Number Agreed	4	4	Date Agreed	31/01/2018	4	08/09/2017	4	Recruitment finished	
24	16/SS/0015	196099	A Phase 2 Pilot, Multicenter, Single Arm Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of GSK1070806 plus Standard of Care for the Prevention of Delayed Graft Function in Adult Subjects After Renal Transplantation	Number Agreed	3	3	Date Agreed	30/04/2017	1	30/04/2017	1	Withdrawn by sponsor	Sponsor terminated the program due to a insufficiently low success rate with recruitment
25	16/NE/0057	199733	Safety & Efficacy of Tideglusib in Type 1 Myotonic Dystrophy	Range Agreed	8	16	Date Agreed	31/08/2017	16	31/08/2017	16	Recruitment finished	
26	16/EM/0125	198595	Powered Vascular Stapler use in Renal Surgery	Range Agreed	20	45	Date Agreed	31/08/2017	41	25/07/2017	41	Recruitment finished	
27	16/NE/0023	218003	CREAD: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY AND SAFETY STUDY OF CRENEZUMAB IN PATIENTS WITH PRODROMAL TO MILD ALZHEIMER'S DISEASE	Number Agreed	2	2	Date Agreed	31/07/2018	2	01/09/2017	2	Recruitment finished	
28	16/LO/0586	200579	AN OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS WHO HAVE A SUBOPTIMAL RESPONSE TO AN ADEQUATE COURSE OF DISEASE-MODIFYING TREATMENT	Range Agreed	3	8	Date Agreed	31/07/2017	2	13/04/2017	2	Withdrawn by sponsor	Competitive recruitment by sponsor

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
29	16/NW/0567	204090	A prospective, non-interventional study measuring quality of life, patient choice, and treatment satisfaction of Autosomal Dominant Polycystic Kidney Disease patients in Europe.	Number Agreed	20	20	Date Agreed	31/12/2017	20	30/06/2017	20	Recruitment finished	
30	16/ES/0026	198532	Effectiveness of adalimumab in moderate to severe Hidradenitis Suppurativa patients - a Multi centre study in real life setting - HARMONY Study	Number Agreed	5	5	Date Agreed	31/03/2018	5	08/09/2017	5	Recruitment finished	
31	14/NI/1033	147734	A Phase 1 open-label multicentre dose-escalation study of subcutaneous ALM201 in patients with advanced ovarian cancer and other solid tumours	Number Agreed	10	10	Date Agreed	27/12/2018	9	19/07/2017	9	Withdrawn by sponsor	Competitive recruitment by sponsor
32	16/SC/0542	208245	A multicenter, Open-Label, Extension Study To Evaluate The Long-Term Safety And Tolerability Of Lampalizumab In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration Who Have Completed A Roche-Sponsored Study.	Number Agreed	1	1	Date Agreed	30/09/2017	1	06/09/2017	1	Recruitment finished	
33	17/LO/0212	221502	An open label, active comparator extension trial to assess the effect of long term dosing of inclisiran and evolocumab given as subcutaneous injections in subjects with high cardiovascular risk and elevated LDL-C (ORION-3)	Number Agreed	3	3	Date Agreed	31/07/2017	3	31/07/2017	3	Recruitment finished	
34	16/NE/0259	209692	Open label, Extension Study to Assess the Long Term Safety and Efficacy of UX007 in Subjects with Glucose Transporter Type-1 Deficiency Syndrome	Number Agreed	2	2	Date Agreed	15/09/2017	2	15/09/2017	2	Recruitment finished	
35	16/NW/0787	216022	A phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis harbouring one F508del CFTR mutation and a second gating (class III) mutation	Range Agreed	1	2	Date Agreed	18/08/2017	1	18/08/2017	1	Recruitment finished	
36	17/EM/0006	216496	A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine	Range Agreed	1	3	Date Agreed	05/10/2017	1	07/07/2017	1	Withdrawn by sponsor	Competitive recruitment by sponsor
37	15/LO/0090	167304	A Phase 2a, Randomized, Placebo-controlled, Proof of Mechanism Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Subjects with Primary Sjogren's Syndrome	Range Agreed	3	5	Date Agreed	30/06/2017	4	30/06/2017	4	Recruitment finished	
38	16/LO/2104	215567	Incidence, outcomes and standard of care of adenovirus infections in hematopoietic cell transplant recipients	Number Agreed	7	7	Date Agreed	10/11/2017	22	23/05/2017	22	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
39	16/NE/0031	193654	Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic response of Foxy-5 in Patients with Metastatic Breast-, Colon- or Prostate Cancer.	Number Agreed	8	8	Date Agreed	31/08/2017	3	31/08/2017	3	Recruitment finished	Rectal patients were not eligible as a new standard treatment became available, so referrals dried-up. The sponsor opened the UK-only slots to Denmark
40	16/ES/0004	192492	A Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Olaparib (PARP inhibitor) in Patients with Advanced Solid Tumors	Number Agreed	5	5	Date Agreed	30/09/2017	4	30/09/2017	4	Recruitment finished	Several patients were screened but unfortunately only 4 patients were suitable for the study
41	16/WS/0109	199365	A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BIB074 in Subjects With Neuroopathic Pain From Lumbosacral Radiculopathy	Number Agreed	1	1	Date Agreed	08/08/2017	0	08/08/2017	0	Recruitment finished	Unable to find a suitable patient who fitted the study criteria
42	15/WS/0160	174507	Safety and Efficacy of the CARILLON Mitral Contour System® in Reducing Functional Mitral Regurgitation (FMR) Associated with Heart Failure	Range Agreed	3	6	Date Agreed	30/09/2017	1	31/07/2017	1	Withdrawn by sponsor	By the time the study was initiated the trial was almost complete and patients suitable were difficult to identify
43	11/EM/0398	87747	A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients with Type 2 Diabetes Mellitus)	Number Agreed	1	1	Date Agreed	03/07/2017	1	02/07/2017	1	Recruitment finished	
44	13/SC/0173	108971	VIALE: A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/PCa Versus Placebo in Men with Metastatic Castration Resistant Prostrate Cancer Eligible for 1st Line Chemotherapy	Range Agreed	6	8	Date Agreed	16/11/2018	6	07/10/2017	6	Recruitment finished	
45	15/NE/0204	182876	PROSPER: Prospective Real World Outcomes Study of Hepatic Encephalopathy Patients' Experience on Rifaximin-a (TARGAXAN®/XIFAXAN®)550 mg	Range Agreed	4	12	Date Agreed	31/12/2017	11	30/09/2017	11	Recruitment finished	
46	15/LO/1118	180199	A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects with NUT Midline Carcinoma (NMC) and Other Cancers	Number Agreed	5	5	Date Agreed	30/06/2025	1	18/12/2017	1	Withdrawn by sponsor	Sponsor closed enrollment to the study because the initial data appeared there was limited or no significant benefit of treatment with GSK525762 as a single agent in subjects
47	14/SC/1161	17382	Prospective, single-arm, multi-centre, observational registry to further validate safety and efficacy of the ultimaster DES in real-world patients.	Range Agreed	50	100	Date Agreed	31/05/2018	100	30/11/2017	100	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
48	15/LO/1289	18607	Multicenter, randomized, double-blind, placebo-controlled phase 3 trial investigating the efficacy and safety of Rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease undergoing lower extremity revascularization procedures	Range Agreed	5	8	Date Agreed	31/01/2018	6	12/12/2017	6	Recruitment finished	
49	15/SC/0409	18465	Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration	Number Agreed	5	5	Date Agreed	01/07/2017	4	07/04/2017	4	Recruitment finished	Although 6 were recruited 2 screen failed, as it was competitive recruitment the study closed before the team were able to recruit any more
50	15/EE/0301	173689	A prospective, international, longitudinal, observational disease registry of patient-reported outcomes (PROs), and the association with Hemophilia A and its treatment in patients with moderate to severe Hemophilia A.	Range Agreed	10	40	Date Agreed	31/08/2018	41	04/12/2017	41	Recruitment finished	
51	15/WS/0282	18747	Safety & Efficacy of Lenalidomide with MOR00208 in R-R DLBCL Patients	Range Agreed	2	6	Date Agreed	31/10/2017	3	31/10/2017	3	Recruitment finished	
52	15/LO/0781	171789	Evaluation of the safety and efficacy of PAD ciclosporin in dry eye patients	Number Agreed	1	1	Date Agreed	01/11/2017	1	01/11/2017	1	Recruitment finished	
53	15/SC/0456	174561	An Early-Phase, Multicenter, Open-Label Study Of The Safety And Pharmacokinetics Of Anti-PD-L1 Antibody (MPDL3280A) In Pediatric And Young Adult Patients With Previously Treated Solid Tumors	Range Agreed	1	3	Date Agreed	30/09/2017	1	29/09/2017	1	Recruitment finished	
54	16/NW/0238	183403	DRAKO Non-interventional Study	Range Agreed	10	25	Date Agreed	31/12/2017	10	31/12/2017	10	Recruitment finished	
55	17/ES/0030	216486	PHASE IV OPEN LABEL SINGLE GROUP ONE YEAR STUDY OF HOME SELF-INJECTION WITH SAYANA® PRESS IN ADULT WOMEN OF REPRODUCTIVE AGE	Number Agreed	10	10	Date Agreed	20/04/2018	1	01/12/2017	1	Withdrawn by sponsor	Main site reached their target and therefore closed the study earlier than planned
56	16/EM/0007	190428	Global multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivAroxaban-based antithrombotic strategy to an antiplatelet-based strategy after transcatheter aortic valve rEplacement (TAVR) to Optimize clinical outcomes.	Number Agreed	4	4	Date Agreed	31/12/2018	4	02/10/2017	4	Recruitment finished	
57	16/NS/0070	208445	The HeartFlow ADVANCE Registry: Assessing Diagnostic Value of Non-invasive FFRCT in Coronary CarE	Range Agreed	3	6	Date Agreed	29/06/2021	4	31/10/2017	4	Recruitment finished	
58	16/LO/0803	204170	Study of MiniMed™ 640G Insulin Pump with SmartGuard™ in prevention of Low Glucose Events in adults with Type 1 diabetes	Number Agreed	7	7	Date Agreed	01/12/2017	0	01/12/2017	0	Withdrawn by sponsor	No patients were recruited and Newcastle was closed as a site by the sponsor
59	16/NE/0399	215044	A Long-Term Extension Study of the Safety and Tolerability of RVT-101 in Subjects with Dementia with Lewy Bodies (DLB)	Number Agreed	4	4	Date Agreed	31/10/2017	1	09/10/2017	1	Recruitment finished	Only one patient from the original study was eligible to continue

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
60	16/LO/1891	213918	A Phase 2, Double-Blind, Randomized Study Evaluating the Safety, Tolerability, and Efficacy of GS-4997 in Combination with Prednisolone versus Prednisolone Alone in Subjects with Severe Alcoholic Hepatitis (AH)	Range Agreed	1	3	Date Agreed	21/12/2017	1	13/12/2017	1	Recruitment finished	
61	17/EM/0116	222773	A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa-Treated Patients with Parkinson's Disease Experiencing End of Dose "Wearing-Off"	Range Agreed	3	6	Date Agreed	30/06/2018	0	20/11/2017	0	Withdrawn by sponsor	The sponsor discontinued the tozadenant development program, an investigational treatment for Parkinson's disease. Based on new information obtained from the Phase 3 program relating to previously agranulocytosis and associated serious adverse events.
62	16/NE/0386	217871	VBP15-002 A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)	Range Agreed	4	6	Date Agreed	31/10/2017	6	31/08/2017	6	Recruitment finished	
63	16/NE/0387	218683	Amended Clinical Protocol #1 for a Phase II Open-label, Multicenter Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD).	Number Agreed	7	7	Date Agreed	02/03/2018	7	31/10/2017	7	Recruitment finished	
64	16/EE/0463	214371	An open-label, multicenter, Phase IIIb study to assess the safety and efficacy of ribociclib (LEE011) in combination with letrozole for the treatment of men and postmenopausal women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC) with no prior hormonal therapy for advanced disease	Number Agreed	3	3	Date Agreed	31/01/2018	1	06/11/2017	1	Withdrawn by sponsor	Newcastle recruited one patient before the study was closed by the sponsor
65	16/NE/0311	211096	A real world study to describe the impact of AbbVie Care on patient quality of life and experience and NHS resource use in inflammatory bowel disease, rheumatoid arthritis, psoriasis, psoriatic arthritis and ankylosing spondylitis in the UK (AMORE)	Number Agreed	6	6	Date Agreed	30/11/2017	6	14/09/2017	6	Recruitment finished	
66	16/SC/0676	217183	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Sclerosing Cholangitis Without Cirrhosis	Number Agreed	1	1	Date Agreed	31/10/2017	0	31/10/2017	0	Recruitment finished	The clinical team were actively looking for patients however, they didn't identify any in clinic who fitted the strict eligibility criteria

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
67	16/LO/1810	209789	A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)	Number Agreed	1	1	Date Agreed	31/05/2018	1	12/10/2017	1	Recruitment finished	
68	16/WM/0433	215494	A research study to describe the "real world" use of Thrombopoietin-Receptor Agonists (TRAs) in the management of Immune Thrombocytopenia (ITp) in the UK	Number Agreed	10	10	Date Agreed	31/10/2017	10	31/10/2017	10	Recruitment finished	
69	17/NE/0270	231054	Serum sample collection to determine analytical performance characteristics of the ADVIA CENTAUR® Free Beta Human Chorionic Gonadotropin assay	Number Agreed	150	150	Date Agreed	16/02/2018	173	19/12/2017	173	Recruitment finished	
70	17/NE/0201	218005	A Prospective Observational Study of Patients with Primary Mitochondrial Disease (SPIMM-300)	Number Agreed	5	5	Date Agreed	31/08/2018	9	06/09/2017	9	Recruitment finished	
71	16/EE/0357	206501	Opicapone in clinical practice	Range Agreed	4	8	Date Agreed	13/12/2017	4	13/12/2017	4	Recruitment finished	
72	16/SC/0391	208610	A randomized, double-blind, double-dummy, parallel-group study comparing the efficacy and safety of ofatumumab administered subcutaneously versus teriflunomide administered orally in patients with relapsing forms of multiple sclerosis	Number Agreed	3	3	Date Agreed	27/12/2017	0	14/12/2017	0	Withdrawn by sponsor	Due to fast Global recruitment the sponsor was able to close the study early. No patients were recruited at Newcastle
73	16/SC/0566	213579	A MULTICENTRE CLINICAL INVESTIGATION OF MAGNETICALLY ENHANCED DIFFUSION FOR ACUTE ISCHEMIC STROKE (MEDIS)	Number Agreed	3	3	Date Agreed	31/12/2017	0	31/12/2017	0	Withdrawn by sponsor	The sponsor closed the arm of the trail that was going to use their microbeads a form of Intra venous placement-worldwide. They are now looking at developing a treatment in partnership with clot retrieval equipment to use the microbeads in the inter arterial form
74	17/LO/0683	226533	A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX-659 Combination Therapy in Subjects Aged 18 Years and Older With Cystic Fibrosis	Range Agreed	1	4	Date Agreed	12/12/2017	3	12/12/2017	3	Recruitment finished	
75	17/NE/0165	217768	AN OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB IN PATIENTS WITH EARLY STAGE RELAPSING REMITTING MULTIPLE SCLEROSIS	Range Agreed	2	6	Date Agreed	31/05/2018	2	12/03/2018	2	Withdrawn by sponsor	Competitive recruitment by sponsor
76	17/LO/0096	220205	A Phase 3b, 12-month, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of BIIB019, Daclizumab, in Subjects with Relapsing-Remitting Multiple Sclerosis (RRMS) Switching from Natalizumab (SUSTAIN)	Number Agreed	4	4	Date Agreed	01/04/2018	0	08/03/2018	0	Withdrawn by sponsor	Sponsor closed study early following announcement of voluntary worldwide withdrawal of ZINBRYTA (daclizumab) for relapsing multiple sclerosis.
77	12/LO/1257	105896	UTCPh310: Oral UT-15C for treatment of Pulmonary Arterial Hypertension (PAH)	Range Agreed	2	6	Date Agreed	30/04/2018	7	31/12/2017	7	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
78	15/LO/1226	163213	Onyx CFZ008: Phase 1b/2 Study of Carfilizomib in Combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (UK R3 Induction Backbone) in Children with Relapsed or Refractory Acute Lymphoblastic Leukemia	Number Agreed	1	1	Date Agreed	22/09/2017	0	22/09/2017	0	Withdrawn by sponsor	Due to contractual difficulties Newcastle's site was closed early
79	16/EM/0512	215840	A PHASE III, DOUBLE-BLINDED, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS COBIMETINIB AND VEMURAFENIB VERSUS PLACEBO PLUS COBIMETINIB AND VEMURAFENIB IN PREVIOUSLY UNTREATED BRAFV600 MUTATION-POSITIVE PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC MELANOMA	Range Agreed	1	3	Date Agreed	31/10/2018	1	30/03/2018	1	Recruitment finished	
80	16/NE/0321	211563	A Phase 2, Double-Blind, Placebo-Controlled Study of RSLV-132 in Subjects with Primary Sjogren's Syndrome	Range Agreed	14	28	Date Agreed	01/02/2018	22	01/02/2018	22	Recruitment finished	
81	15/LO/0528	174833	Evaluating the use of wearable technology and smart phone apps to monitor paediatric diseases	Range Agreed	5	20	Date Agreed	01/02/2018	25	01/02/2018	25	Recruitment finished	
82	15/LO/1950	184545	A Randomized Placebo Controlled Phase 2b/3 Study of ABT-414 in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intelligence 1)	Range Agreed	1	5	Date Agreed	20/04/2018	2	15/01/2018	2	Recruitment finished	
83	16/SC/0677	217105	A Phase 2, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Safety, Tolerability, and Efficacy of GS-9674 in Subjects with Primary Biliary Cholangitis Without Cirrhosis	Number Agreed	2	2	Date Agreed	31/10/2017	0	31/10/2017	0	Withdrawn by sponsor	No patients was identified due to the strict eligibility criteria
84	15/NE/0143	174391	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ETROLIZUMAB AS AN INDUCTION AND MAINTENANCE TREATMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE	Range Agreed	2	3	Date Agreed	17/11/2017	2	17/11/2017	2	Recruitment finished	
85	15/NW/0592	185435	randomised, double-blinded, double-dummy, placebo-controlled, parallel-group multi-centre exploratory clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus (T1DM) investigating the effect of the IMP and a long-acting glucagon-like peptide-1 agonist (GLP-1 agonist) on beta-cell preservation	Range Agreed	1	2	Date Agreed	01/09/2017	4	01/09/2017	4	Recruitment finished	

Number	Research Ethics Committee Reference Number	Integrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to recruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
86	16/SC/0530	213306	Evaluating the tolerance, compliance, acceptability and safety of Ketocal 2.5:1 LQ, a nutritionally complete liquid feed for use as part of the Ketogenic Diet in children 8+ years, adolescents and adults with intractable epilepsy or other disorders where the KD is indicated	Number Agreed	3	3	Date Agreed	13/12/2018	3	30/03/2018	3	Recruitment finished	
87	17/LO/0849	222165	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)	Number Agreed	3	3	Date Agreed	30/01/2019	4	31/01/2018	4	Recruitment finished	
88	16/WM/0409	204629	Global Treatment Patterns, Health Care Resource Utilization, and Survival Outcomes among Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck	Range Agreed	6	10	Date Agreed	15/01/2018	7	15/01/2018	7	Recruitment finished	
89	17/LO/1147	222154	Tralokinumab monotherapy for moderate-to-severe atopic dermatitis ECZTRA 2 (ECZema TRAlokinumab trial no. 2)	Number Agreed	6	6	Date Agreed	01/07/2018	7	23/03/2018	7	Recruitment finished	
90	16/WM/0471	215399	An 8-week, dose ranging, open label, randomized, Phase 2 study with an 18-week extension, to evaluate the safety and efficacy of MBX-8025 in subjects with Primary Biliary Cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)	Range Agreed	2	4	Date Agreed	15/07/2018	4	30/03/2018	4	Recruitment finished	
91	17/WS/0165	226413	A Single Arm, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Glecaprevir(GLE)/Pibrentasvir(PIB) in Treatment Naïve Adults with Chronic Hepatitis C Virus (HCV) Genotypes 1 – 6 Infection and Aspartate aminotransferase to Platelet Ratio Index (APRI) ≤ 1	Range Agreed	2	6	Date Agreed	24/01/2018	5	24/01/2018	5	Recruitment finished	
92	17/NI/0367	237110	A 24-month Phase II Open-label, Multicenter Long-term Extension Study to Assess the Long-term Safety and Efficacy of Vamorolone in Boys with Duchenne Muscular Dystrophy (DMD)	Number Agreed	7	7	Date Agreed	05/05/2020	7	16/03/2018	7	Recruitment finished	
93	17/SC/0028	218036	A Double-Blind, Randomized, Two Arm Phase 2 Study of Nivolumab in Combination with Ipilimumab versus Nivolumab in Combination with Ipilimumab Placebo In Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)	Number Agreed	4	4	Date Agreed	30/03/2018	1	26/02/2018	1	Recruitment finished	Competitive recruitment by sponsor meant the study closed early than planned